Brokerages expect Aduro BioTech Inc (NASDAQ:ADRO) to announce ($0.30) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Aduro BioTech’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.37). Aduro BioTech posted earnings per share of ($0.32) in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The company is expected to announce its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Aduro BioTech will report full-year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.01). For the next year, analysts expect that the company will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.68) to $0.03. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. The business had revenue of $3.76 million for the quarter, compared to analyst estimates of $4.32 million. Aduro BioTech had a negative net margin of 532.88% and a negative return on equity of 37.86%.
ADRO stock remained flat at $$7.10 during midday trading on Friday. 198,982 shares of the company traded hands, compared to its average volume of 590,069. The firm has a market capitalization of $603.50, a price-to-earnings ratio of -4.98 and a beta of 2.07. Aduro BioTech has a 1-year low of $5.82 and a 1-year high of $14.05.
In other news, insider Elsas Andrea Van sold 6,874 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.48, for a total transaction of $44,543.52. Following the completion of the sale, the insider now directly owns 216,669 shares of the company’s stock, valued at $1,404,015.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stephen T. Isaacs sold 72,051 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $8.48, for a total transaction of $610,992.48. Following the sale, the insider now directly owns 231,380 shares of the company’s stock, valued at $1,962,102.40. The disclosure for this sale can be found here. Insiders have sold 118,925 shares of company stock worth $1,011,936 in the last quarter. Company insiders own 6.60% of the company’s stock.
Large investors have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of Aduro BioTech during the fourth quarter worth about $1,309,000. Wells Fargo & Company MN increased its position in shares of Aduro BioTech by 111.5% during the third quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock worth $776,000 after acquiring an additional 38,415 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Aduro BioTech during the fourth quarter worth about $592,000. Virtus Fund Advisers LLC bought a new stake in shares of Aduro BioTech during the fourth quarter worth about $321,000. Finally, Vident Investment Advisory LLC increased its position in shares of Aduro BioTech by 40.4% during the fourth quarter. Vident Investment Advisory LLC now owns 154,140 shares of the biotechnology company’s stock worth $1,156,000 after acquiring an additional 44,325 shares in the last quarter. 44.91% of the stock is owned by institutional investors.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.